http://ca.finance.yahoo.com/q/bc?s=ISA.TO&t=3m

http://www.isotechnika.com/in_development/

http://clinicaltrials.gov/ct2/results?term=isotechnika

http://www.fpinfomart.ca/fpsn/snap_display.php?key=fp|fpsn|30073

Isotechnika Pharma Inc.
5120 75 St
Edmonton, AB
T6E 6W2
Tel: (780) 487-1600
Toll-free: (888) 487-9944
Fax: (780) 484-4105

Contact Name
Dennis Bourgeault

Industry
Biotechnology
 

Key Executives
Robert T. Foster, CEO
Dennis Bourgeault, CFO

Discovers, develops and plans to commercialize immunosuppressive therapeutic drugs for the treatment of autoimmune diseases and for use in the prevention of organ rejection in transplantation. Also develops and sells diagnostic products and services.
FP ADVISOR COVERAGE
Isotechnika Pharma Inc.
FP Corporate Analyzer
FP Directory of Directors
FP Corporate Surveys
FP Investor Reports
FP Predecessor & Defunct
Ordering FP Products
 
TOP INDUSTRY PLAYERS
Biotechnology
Company Name Revenue (
00s) 
Atrium Innovations Inc. 364,726
Angiotech Pharmaceuticals, Inc. 319,113
QLT Inc. 132,457
Oncothyreon Inc. 42,678
AEterna Zentaris Inc. 41,056
(Links are to Snapshots.)
 
FINANCIAL RATIOS AS OF MAR. 19/10
Listed Close 52-wk
High
52-wk
Low
IAD Latest
Dividend
Yield 60-mo
Beta
TSX/ISA
.40

.42 on
Mar. 19/10

.12 on
Apr. 13/09
n.a. n.a. n.a. 1.17
Avg 20-day
Volume
P/E 12-mo
EPS
EPS
Date
1-yr
Return
3-yr
Return
5-yr
Return
Market
Cap (000s)
232,853 n.a. $ -0.10 Sept. 30/09 166.67% -33.66% -31.69% $52,526
 
ANNUAL FINANCIALS
Periods ended: 12m Dec. 31/08 12m Dec. 31/07 12m Dec. 31/06

00s

00s

00s
Operating revenue 4,718 2,312 4,106
Net income (19,328) (33,494) (26,637)
Total assets 32,443 42,253 35,710
$ $ $
Earnings per share* (0.18) (0.32) (0.32)
% % %
Return on equity (102.49) (129.71) (73.28)
 
* Common
 
TRAILING 12-MONTH VALUES
Periods ended: Sept. 30/09 Sept. 30/08

00s

00s
Operating revenue 3,274 4,611
Net income (11,245) (22,941)
$ $
Earnings per share (0.09) (0.22)